MAPK3 and Parkinson disease: In Parkinson’s disease (PD), CGA inhibits the excessive production of ROS through the AKT/Erk1/2 pathway, thereby reducing axonal damage and neuronal apoptosis in the 6-hydroxydopamine-induced PD mice.